All three models highlight LLY's massive Q2 earnings beat (EPS $8.55 vs $6.79) and 48% YoY revenue growth driven by Mounjaro and Zepbound as a primary catalyst for a sustained re-rating. Analysts agree that the raised full-year guidance and rising RSI from oversold conditions support a continuation toward targets of $1208 to $1249.45. A pullback to the $1135–$1156 support zone is identified as an attractive entry point to ride momentum back through the $1180 resistance cluster, supported by a favorable macro regime and sector confirmation from the XLV.
All three models warn that LLY is facing significant exhaustion at the $1180–$1182 resistance cluster, noting that the post-earnings gap-up is vulnerable to a 'sell the news' mean-reversion fade. Despite the strong growth, models point to a premium valuation (39.8 P/E) and technical rejection at the 4h SMA 20/50 as triggers for a pullback toward the $1139–$1140 support level. Unique risks include declining 30-minute MACD momentum and broader macro tail risks, such as defensive hedging in gold and yen strength, which may pressure high-multiple stocks over a 1-3 week horizon.
- →A daily close below the $1130–$1139 support zone invalidates the long thesis, signaling that the post-earnings catalyst has been fully faded.
- →A 4-hour close below $1156.32 or a failure to gain acceptance above $1182 resistance indicates a loss of momentum and potential trend reversal.
Individual Model Analysis
Bull/Bear CompetitionWinner: BULL
LLY posted a strong Q2 2026 beat on Aug 5 with revenue +48% YoY driven by Mounjaro/Zepbound and raised full-year guidance, sending shares up ~7% and repairing the technical picture after a pullback from the highs. With a fresh dated catalyst, sector confirmation from XLV, and a bullish equity regime, a retest of 4h support around $1156 offers a favorable entry to ride the earnings-driven re-rating back toward the SMA 20/resistance cluster near $1180 and the high-volume node above. Momentum is turning up (RSI rising, MACD histograms improving) as buyers reassert control off the raised guidance.
LLY gapped ~7% on strong Q2 earnings into a resistance cluster at $1180 (4h resistance $1180.23, SMA20 $1171.81, 1day resistance $1182.03) while the stock remains below its 4h SMA 20/SMA 50, leaving the earnings pop vulnerable to a mean-reversion fade back toward the value-area low and 1day support near $1140. A short is best expressed as a limit fade into the $1178-1180 supply zone rather than at current price, targeting the gap-fill/support retest as post-earnings enthusiasm cools over the 1-3 week swing. The elevated near-term IV (69.9%) and gold-hedging crosscurrents in the regime suggest the rally is being hedged, not fully trusted.
Bull/Bear CompetitionWinner: BULL
LLY surged +3.95% on Aug 5 after a massive Q2 earnings beat (EPS $8.55 vs $6.79 est, +48% revenue, raised full-year guidance) , driven by blockbuster Mounjaro/Zepbound GLP-1 sales. The stock is still below its first major resistance at $1180-1182 and 4h RSI at 48.9 is just turning up from neutral, leaving room for follow-through as the market reprices the higher guidance. A pullback to the $1135 support zone (near 1d support and 30m support) offers an attractive limit entry to ride the post-earnings momentum toward the value area POC at $1208 and beyond.
LLY surged ~7% on Aug 5 after strong Q2 earnings, but the intraday fade from the open high suggests a classic "buy the rumor, sell the news" exhaustion pattern as the gap-up is being rejected near the 4h resistance zone ( $1180) . With premium valuation (P/E 39.8, Fwd P/E 24.9) leaving little room for error and lower-timeframe momentum already rolling over (30-min RSI falling, MACD histogram declining) , the stock is vulnerable to a mean-reversion fade back toward the pre-earnings range over the next 1-3 weeks. The narrow breadth regime with defensive hedging (gold surging, yen strength) adds risk-off tail risk for high-multiple names.
Bull/Bear CompetitionWinner: BULL
LLY presents a compelling long case following its Aug. 5 earnings report, which delivered a 48% year-over-year revenue growth and beat analyst estimates, driven by strong performance in its GLP-1 drugs Mounjaro and Zepbound. The company also raised its full-year revenue guidance, signaling confidence in sustained demand and pricing power. With price currently retracing toward the 4h support level of $1156.32 and RSI rising from oversold conditions, the stock is poised for a continuation toward its recent highs near $1249.45, supported by bullish sector confirmation and a favorable macro regime.
LLY has surged post-earnings on August 5, 2026, driven by a 48% revenue growth beat and raised full-year guidance, but the move has left the stock extended at key resistance levels ( $1180.23 on the 4h timeframe and $1182.03 on the 1d timeframe) . The stock is now trading near its 52-week high (-7.2%) with RSI (48.89) rising but not yet overbought, suggesting a potential exhaustion of the post-earnings rally. The broader regime remains bullish, but LLY's rapid ascent into resistance, coupled with a lack of confirmed acceptance above these levels, sets up a high-probability pullback toward support at $1139.31 (1day) or lower.